Investment
Features
FeesSafety
Academy
More
Pluang+

Hooker Furnishings Q2 earnings beat estimates despite revenue decline amid housing market weakness

Company Fundamentals
11 Sep 2026
Andrew Wynn
View Source
Neutral
Hooker Furnishings Q2 earnings beat estimates despite revenue decline amid housing market weakness

Hooker Furnishings reported Q2 fiscal 2027 earnings of $0.11 per share from continuing operations, beating analyst expectations of a $0.02 loss per share, while total diluted EPS including discontinued operations was $0.15. However, quarterly net sales fell 8.7% year-over-year to $63.25 million, slightly missing estimates due to lower sales volumes and ongoing housing market weakness. The company’s profitability improved thanks to tariff recoveries and cost reductions, resulting in a net income of approximately $1.7 million compared to a loss last year. Despite revenue challenges, improved margins and cost savings support a cautiously optimistic outlook.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
McDonald's shares drop over 30%, a rare plunge linked to rising US Treasury yields.

McDonald's shares drop over 30%, a rare plunge linked to rising US Treasury yields.

McDonald's stock has fallen more than 30%, a rare event seen only a few times in 40 years, mainly due to rising US 10-year Treasury yields making safer investments more attractive compared to McDonald's dividend. Despite the price drop, McDonald's fu...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App